Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Alliance to Develop Cancer Assays

By HospiMedica staff writers
Posted on 29 Aug 2002
An alliance to develop cancer diagnostic assays has been announced by Fujirebio Diagnostics, Inc. More...
(FDI, Malvern, PA, USA) and Randox, Ltd. (Crumlin, UK). The two companies will combine their proprietary technologies in the development of the assays.

Under the terms of the agreement, FDI has given Randox exclusive rights to develop and commercialize a tumor marker assay panel incorporating FDI's antibodies used in the CA125II, CA19-9, CA15-3, CA72-4 and Truquant tumor marker assays, for use on Randox's biochip array. The automated biochip technology allows the simultaneous determination of a panel of diagnostic markers from a single patient sample. The markers can be used in combination or as stand-alone tests. Recent studies have shown that multiplexing assay determinations using the same patient sample may improve diagnostic performance.

"The agreement with Randox is in line with our corporate strategy of being a content-driven diagnostics company and allows our standard-of-care markers to be formatted on a cutting-edge platform,” said Aris Petropoulos, president and chief operating officer, Fujirebio Diagnostics.



Related Links:
Fujirebio Diagnostics, Inc
Randox, Ltd

Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
POC Respiratory/Sore Throat Test
BIOFIRE SPOTFIRE (R/ST) Panel
Surgical System
Stealth AXiS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Medical Imaging

view channel
Images from patient T1, who had menstrual cycle–dependent right shoulder pain. (A) Maximum-intensity-projection images show abnormal findings for right diaphragm (arrowhead), bilateral round ligaments, peritoneum around bilateral ovaries, and left fallopian tube. Combined PET/MRI show hyperintense lesion with focal uptake inferior of right diaphragm, indicative of endometriosis (arrowhead, B). Confirmatory laparoscopy demonstrated extensive pelvic disease and implants of right diaphragm (C) that stained intensely positive for FAP (D).  (Image Credit: Schindler P, Brandt J, Bobe S, et al. Initial results of FAPI PET/MRI to assess the extent of endometriosis. J Nucl Med. 2026;67(8):1232–1238. doi:10.2967/jnumed.125.271376)

Targeted PET/MRI Improves Detection and Preoperative Mapping of Endometriosis

Endometriosis is a chronic inflammatory condition in which endometrial-like tissue grows outside the uterus, causing pelvic pain, infertility, and reduced quality of life. Conventional imaging can underestimate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.